CTOR (Citius Oncology, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CTOR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-22 | Jaime Bartushak | Chief Financial Officer | A | — | — |
| 2025-12-22 | Robert Joseph Smith | Director | A | — | — |
| 2025-12-22 | Suren G Dutia | Director | A | — | — |
| 2025-12-22 | Leonard L Mazur | Chief Executive Officer | A | — | — |
| 2025-12-22 | MYRON Z HOLUBIAK | Secretary | A | — | — |
| 2025-12-22 | Carol Webb | Director | A | — | — |
| 2025-12-22 | Joel David Mayersohn | Director | A | — | — |
| 2025-12-22 | Eugene Myron Holuka | Director | A | — | — |
| 2025-12-22 | Myron Czuczman | Chief Medical Officer | A | — | — |
| 2025-12-22 | DENNIS M MCGRATH | Director | A | — | — |
| 2025-12-01 | Carol Webb | Director | A | — | — |
| 2025-12-01 | MYRON Z HOLUBIAK | Secretary | A | — | — |
| 2025-12-01 | Myron Czuczman | Chief Medical Officer | A | — | — |
| 2025-12-01 | DENNIS M MCGRATH | Director | A | — | — |
| 2025-12-01 | Joel David Mayersohn | Director | A | — | — |
| 2025-12-01 | Suren G Dutia | Director | A | — | — |
| 2025-12-01 | Jaime Bartushak | Chief Financial Officer | A | — | — |
| 2025-12-01 | Eugene Myron Holuka | Director | A | — | — |
| 2025-12-01 | Leonard L Mazur | Chief Executive Officer | A | — | — |
| 2025-12-01 | Robert Joseph Smith | Director | A | — | — |
| 2025-09-23 | Robert Joseph Smith | Director | A | — | — |
| 2025-09-23 | Leonard L Mazur | Chief Executive Officer | A | — | — |
| 2025-09-23 | Suren G Dutia | Director | A | — | — |
| 2025-09-23 | Carol Webb | Director | A | — | — |
| 2025-09-23 | MYRON Z HOLUBIAK | Secretary | A | — | — |
| 2025-09-23 | Myron Czuczman | Chief Medical Officer | A | — | — |
| 2025-09-23 | Jaime Bartushak | Chief Financial Officer | A | — | — |
| 2025-09-23 | Eugene Myron Holuka | Director | A | — | — |
| 2025-09-23 | DENNIS M MCGRATH | Director | A | — | — |
| 2025-09-23 | Joel David Mayersohn | Director | A | — | — |
| 2025-08-07 | Joel David Mayersohn | Director | J | — | — |
| 2024-12-16 | Eugene Myron Holuka | Director | A | — | — |
| 2024-12-16 | Suren G Dutia | Director | A | — | — |
| 2024-12-16 | Robert Joseph Smith | Director | A | — | — |
| 2024-12-16 | DENNIS M MCGRATH | Director | A | — | — |
| 2024-12-16 | Carol Webb | Director | A | — | — |
| 2024-12-16 | MYRON Z HOLUBIAK | Secretary | A | — | — |
| 2024-12-16 | Jaime Bartushak | Chief Financial Officer | A | — | — |
| 2024-12-16 | Leonard L Mazur | Chief Executive Officer | A | — | — |
| 2024-12-16 | Joel David Mayersohn | Director | A | — | — |
| 2024-12-16 | Myron Czuczman | Chief Medical Officer | A | — | — |
| 2024-08-30 | Jaime Bartushak | Chief Financial Officer | A | — | — |
| 2024-08-30 | Leonard L Mazur | Chief Executive Officer | A | — | — |
| 2024-08-30 | Myron Czuczman | Chief Medical Officer | A | — | — |
| 2024-08-30 | MYRON Z HOLUBIAK | Director | A | — | — |
| 2024-08-16 | Eugene Myron Holuka | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 1,700,000 | — |
| — | Secretary | 950,000 | — |
| — | Chief Financial Officer | 825,000 | — |
| — | Chief Medical Officer | 825,000 | — |
| — | Director | 321,228 | — |
| — | Director | 300,000 | — |
| — | Director | 300,000 | — |
| — | Director | 300,000 | — |
| — | Director | 300,000 | — |
| — | Director | 300,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CTOR quote page; the site-wide leaderboard is on the insider transactions hub.